Skip to main content
. 2021 Jun 15;41(11-12):1222–1239. doi: 10.1177/03331024211018137

MEDLINE – SEARCH

Concept 1 Search # Concept 2 Search # Concept 3 Search # Concept 4
#1 migraine[Text Word] #11 preventive therapy[Text Word] #40 beta-blocker[Text Word] #85 randomized controlled trial[Text Word]
#2 episodic migraine[Text Word] #12 prophylaxis[Text Word] #41 topiramate[Text Word] #86 controlled clinical trial[Text Word]
#3 chronic migraine[Text Word] #13 treatment[Text Word] #42 anticonvu*[Text Word] #87 randomized controlled*[Text Word]
#4 migraine with aura[Text Word] #14 therapies[Title/Abstract] #43 antiepilep*[Text Word] #88 random allocation[Title/Abstract]
#5 migraine without aura[Text Word] #15 prevention[Text Word] #44 topira*[Text Word] #89 Double-Blind Method[MeSH Terms]
#6 migrain*[Text Word] #16 prophylactic[Text Word] #45 valproate[Text Word] #90 Single-Blind Method[MeSH Terms]
#7 cephalgi*[Text Word] #17 preventive treatment[Text Word] #46 valpro*[Text Word] #91 clinical trial[Text Word]
#8 migraine*[Text Word] #18 pharmacologic[Title/Abstract] #47 candesartan[Text Word] #92 clinical trials[Text Word]
#9 cephalalgi*[Text Word] #19 prevent*[Text Word] #48 candesart*[Text Word] #93 Prospective Studies[MeSH Terms]
#10 Migraine Disorders [Mesh Terms] #20 drug*[Text Word] #49 onabotulinum[Text Word] #94 control*[Text Word]
#21 preventative*[Title/Abstract] #50 botox[Text Word] #95 prospectiv*[Text Word]
#22 therapy[Title/Abstract] #51 onabotulinum*[Text Word] #96 Placebos[MeSH Terms]
#23 effective[Title/Abstract] #52 erenumab[Text Word] #97 placebo*[Text Word]
#24 frequency*[Title/Abstract] #53 CGRP[Text Word] #98 random*[Text Word]
#25 reduction[Title/Abstract] #54 anti-CGRP[Text Word] #99 blind*[Text Word]
#26 reduces[Title/Abstract] #55 Calcitonin Gene-Related*[Text Word] #100 Evaluation Studies as Topic[MeSH Terms]
#27 reduced[Title/Abstract] #56 gepants[Text Word] #101 Comparative Study[Publication Type]
#28 attack*[Title/Abstract] #57 *gepant[Text Word] #102 trial*[Text Word]
#29 month*[Text Word] #58 Valproic Acid[MeSH Terms] #103 controll*[Text Word]
#30 therapeutic[Title/Abstract] #59 Botulinum Toxins, Type A[MeSH Terms] #104 efficacy*[Text Word]
#31 effectively[Title/Abstract] #60 Amitriptyline[MeSH Terms] #105 compare*[Text Word]
#32 effect[Title/Abstract] #61 fremanezumab[Supplementary Concept] #106 Clinical Trials as Topic[MeSH Terms]
#33 Prevention and Control[MeSH Terms] #62 TEV-48125[Text Word] #107 *blind*[Text Word]
#34 Drug Therapy[MeSH Terms] #63 galcanezumab[Supplementary Concept] #108 Multicenter Study[Publication Type]
#35 Treatment Outcome [MeSH Terms] #64 eptinezumab[Supplementary Concept] #109 Clinical Studies as Topic[MeSH Terms]
#36 Therapeutic Use [MeSH Subheading] #65 telcagepant[Supplementary Concept] #110 Cross-Over Studies[MeSH Terms]
#37 monthly[Text Word] #66 Propranolol[MeSH Terms] #111 Clinical Trial[Publication Type]
#38 outcome*[Text Word] #67 Metoprolol[MeSH Terms] #112 Drug Evaluation[MeSH Terms]
#39 preventative treatment[Text Word] #68 Nebivolol[MeSH Terms] #113 Preliminary Data[MeSH Terms]
#69 Adrenergic Beta-Antagonists[MeSH Terms] #114 pivot*[Text Word]
#70 Bisoprolol[MeSH Terms] #115 Review Literature as Topic[MeSH Terms]
#71 Flunarizine[MeSH Terms] #116 Systematic Review[Publication Type]
#72 Verapamil[MeSH Terms] #117 Review[Publication Type]
#73 Anticonvulsants[MeSH Terms]
#74 Calcitonin Gene-Related Peptide[MeSH Terms]
#75 Receptors, Calcitonin Gene-Related Peptide[MeSH Terms]
#76 atogepant[Text Word]
#77 rimegepant[Text Word]
#78 Pituitary Adenylate Cyclase-Activating Polypeptide[MeSH Terms]
#79 PACAP*[Text Word]
#80 AMG334[Text Word]
#81 PAC1[Text Word]
#82 filorexant[Text Word]
#83 orexin[Text Word]
#84 LBR-101[Text Word]